Rivastigmine Production Cost Reports

The report provides a detailed analysis essential for establishing a Rivastigmine production plant. It encompasses all critical aspects necessary for Rivastigmine production, including the cost of Rivastigmine production, Rivastigmine plant cost, Rivastigmine production costs, and the overall Rivastigmine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Rivastigmine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Rivastigmine is a medication primarily used in the pharmaceutical industry for the treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. It works as a cholinesterase inhibitor, increasing acetylcholine levels in the brain to improve cognitive function, memory, and daily living activities.

Rivastigmine is administered orally or via a transdermal patch, with the patch form reducing gastrointestinal side effects like nausea. It has shown symptomatic benefits, mainly in patients with aggressive disease courses, and is also being researched for improving gait stability in Parkinson's patients. Beyond its therapeutic use, rivastigmine serves as a valuable compound in research focused on neurodegenerative diseases and cholinesterase inhibition.

The rivastigmine market is driven primarily by the growing global aging population and the increasing prevalence of neurodegenerative diseases such as Alzheimer's and Parkinson's disease dementia. The global rise in the awareness and emphasis on early diagnosis of cognitive disorders boost demand for effective treatments like rivastigmine. Technological advancements in drug delivery systems, especially transdermal patches, improve patient compliance and expand market reach.

Additionally, market growth is also propelled by increasing healthcare expenditure and ongoing research into new therapeutic applications and formulations. However, regulatory compliance is critical, as rivastigmine is a prescription drug subject to varying regulations and registration requirements across regions, which impacts market access and supplier selection, influencing industrial rivastigmine procurement. The presence of generic competition influences pricing and availability, with generic formulations driving prices down but increasing volume sales. Also, patient compliance considerations due to side effects and administration complexity further influence formulation procurement choices (e.g., capsules versus patches).

Raw Material for Rivastigmine Production

According to the Rivastigmine production plant project report, the raw material for Rivastigmine production includes (S)-1-(3-methoxyphenyl)-N-[(S)-1-phenylethyl]ethanamine.

Production Process of Rivastigmine

The extensive Rivastigmine production cost report consists of the following major industrial production process:

1. Production via chemical synthesis: The production process for rivastigmine starts from diastereomerically pure (S)-1-(3-methoxyphenyl)-N-[(S)-1-phenylethyl]ethanamine. This compound undergoes N-methylation using formic acid and formaldehyde to yield an intermediate compound, followed by demethylation of the methoxy group with HBr. The resulting compound reacts with N-ethyl-N-methyl carbamoyl chloride followed by highly regioselective hydrogenolysis due to electron-donating substituents on the aromatic ring to produce the final intermediate. In the final step, N-methylation provides the free base of rivastigmine, which is finally converted to rivastigmine by treatment with L-tartaric acid.

Properties of Rivastigmine

Rivastigmine is a white to off-white fine crystalline powder with the molecular formula C14H22N2O2 and a molecular weight of 250.34 g/mol for the free base and about 400.43 g/mol for its tartrate salt form. It is an organonitrogen compound classified as an aralkylamine, with its chemical IUPAC name being 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate. Rivastigmine has a melting point of 158 degree Celsius and a pKa of 8.8, indicating it is a strong base. It is soluble in water at acidic pH but has limited solubility at neutral pH and is lipophilic enough to cross the blood-brain barrier.

The compound acts as a carbamate cholinesterase inhibitor, reversibly inhibiting acetylcholinesterase and butyrylcholinesterase, which increases acetylcholine concentration in the brain. Rivastigmine exhibits a logP value around 2.4, showing moderate lipophilicity, and is available in oral and transdermal forms. It demonstrates 40% oral bioavailability and undergoes metabolism primarily via cholinesterase-mediated hydrolysis, with minimal involvement of cytochrome P450 enzymes, lowering drug interaction risks.